natgillin/translations-raw huggingface dataset:
A packaging according to claim 1, wherein the width of the packaging is between 134 mm and 138 mm, and the length of the packaging is between 188 mm and 194 mm when packaging is in a closed condition. 
Pakiranje u skladu s patentnim zahtjevom 1, naznačeno time, što je širina pakiranja između 134 i 138 mm, a duljina pakiranja je između 188 i 194 mm, kada je pakiranje u zatvorenom stanju.
The antibody of any one of claims 1-4, wherein the antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 212 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 213. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 5, naznačen time, da protutijelo anti-DLL3 obuhvaća varijabilno područje slabog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:212 1 varijabilno područje jakog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:213.
A kit for preparing the composition of any one of embodiments 1 to 15, wherein the kit comprises at least one meningococcal conjugate in lyophilised form and at least one meningococcal conjugate in aqueous form. 
Pribor za pripremu sastava prema bilo kojem od zahtjeva 1 do 15, naznačen time da pribor sadrži najmanje jedan meningokokni konjugat u liofiličnom obliku i najmanje jedan meningokokni konjugat u vodenom obliku,
FIG. 3 provides another diagram of the receiver used in the present invention, showing the holes used for fastening the receiver to a boat, and also showing dimensions of a preferred embodiment. 
Slika3 je još jedan dijagram prijemnika koji se koristi u opisanom izumu, s prikazanim rupama koje služe pričvršćivanju prijemnika na plovilo, te također s prikazanim dimenzijama u preferiranoj izvedbi.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, pri čemu formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25%C 1 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, koja kada je mjerena na USP aparatu 1 (košara) kod 100 okr/min. u 900 ml simulirane želučane tekućine bez enzima (SGF) na 37C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1, 4 1 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja.
The pharmaceutical composition of claim 19, wherein the orally administrable composition is selected from the group consisting of a tablet, a capsule, a granule, a powder and a syrup. 
Kristalni spoj prema zahtjevu 8, naznačen time, da je autoimuna bolest odabrana iz skupine koju čine: lupus, reumatoidni artritis i prezentacija antigena.
The recombinant anti-a4 antibody molecule, or a4-binding fragment thereof, for use according to claim 5, wherein the patient has multiple sclerosis, asthma, rheumatoid arthritis, diabetes, optic neuritis, or Crohn's disease. 
Rekombinantna molekula protutijela ili njezin fragment koji veže a4, za uporabu prema zahtjevu 4, naznačena time, da pacijent ima čvrsti tumor, hematološko maligno stanje, višestruki mijelom ili akutnu mijeloidnu leukemiju (AML).
The aqueous pharmaceutical suspension according to claim 7, wherein the benzoic acid or sodium benzoate is, by weight/volume (g/100 mL), about 0.12% to about 0.18%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što benzojeva kiselina ili natrijev benzoat iznosi, težinski/volumno (g/100 ml), otprilike 0,12 % do otprilike 0,18 %.
The method of Claim 1 further comprising a preparation of the compound of formula (7), wherein the method comprises treating a compound of formula (6): or a pharmaceutically acceptable salt thereof, under standard Mitsunobu reaction conditions to form the compound of formula (7), or a pharmaceutically acceptable salt thereof. 
S nr O <I ili njegove farmaceutski prihvatljive soli, u standardnim uvjetima za Mitsunobuovu reakciju, kako bi se dobilo spoj formule (7), ili njegovu farmaceutski prihvatljivu sol.
<400> 7 ggaggcggag ggtccggagg cggaggatcc 30 A bispecific antibody or antibody fragment thereof that specifically binds to IL-13 and IL-4, wherein the bispecific antibody or antibody fragment thereof contains two light chains with the structure N-VLhB-B13-linker-VLh8D4-8-CL-C and two heavy chains with the structure N-VHhB-B13-linker-VHh8D4-8-CH1-CH2-CH3-C, wherein CL is the light chain constant region, VLhB-B13 is a humanized light chain variable domain of anti IL-13 antibody B-B13, VLh8D4-8 is a humanized light chain variable domain of anti IL-4 antibody 8D4-8, VHhB-B13 is a humanized heavy chain variable domain of anti IL-13 antibody B-B13, and VHh8D4-8 is a humanized heavy chain variable domain of anti IL-4 antibody 8D4-8; 
Bispecifično antitijelo ili njegov bispecifični fragment antitijela koji se specifično veže na IL-13 1 IL-4, naznačeno time da navedeno bispecifično antitijelo ili njegov bispecifični fragment antitijela sadrži dva laka lanca sa strukturom N-VLyp-Bi3-poveznica-VLypp4.g-CL-C 1 dva teška lanca sa strukturom N-VHu+p.si13-poveznica-V Hypn4-g-CH1-CH2-CH3-C, pri čemu VLyp.Bi3 sadrži sekvencu aminokiseline SEQ ID NO: 1, pri čemu VLiygpa3 sadrži sekvencu aminokiseline SEQ ID NO: 3, pri čemu VH,gp.pia sadrži sekvencu aminokiseline SEQ ID NO: 2, pri čemu VHl,gna.s sadrži sekvencu aminokiseline SEQ ID NO: 5, te pri čemu svaka poveznica je peptidna poveznica koja ima sekvencu aminokiseline koja sadrži SEQ ID NO: 6.
through the following steps: a′) protection of the primary amine of 4-aminomethyl-piperidine (2) 
N O wWac sljedećim koracima: a') zaštita primarnog amina 4-aminometil-piperidina (2)
A use according to claim 16 wherein the disease is either or both of pneumonia or invasive pneumococcal disease (IPD) of elderly humans, exacerbations of chronic obstructive pulmonary disease (COPD) of elderly humans, meningitis and/or bacteraemia of infant humans, otitis media of infant humans or pneumonia and/or conjunctivitis of infant humans. 
Upotreba u skladu s patentnim zahtjevom 16, naznačena time što je bolest bilo koja od ili obje od pneumonija ili invazivna pneumokokna bolesti (IPD) kod starijih ljudi, pogoršanje kronične opstruktivne plućne bolesti (COPD) kod starijih ljudi, meningitis i/ili bakteriemija kod ljudske dojenčadi, upala srednjeg uha kod ljudske dojenčadi ili pneumonija ifili konjunktivitis kod ljudske dojenčadi.
A detachable wall member 21 is positioned inside the tubular member 4, and which is not moulded simultaneously with the tubular member, but inserted therein afterwards. 
Element stijenke 21, koji se može odvojiti, postavljen je unutar cijevnog elementa 4 i nije izliven istovremeno s cijevnim elementom 4, već je naknadno umetnut u njega.
recovering the metallic crusts of the residue material to subsequently recycle them inside the furnace; 
dobivanje metalnih kora (19) rezidualnog materijala kako bi ih se naknadno recikliralo unutar EAF visoke peći (25);
The liquefied gas treatment system according to claim 7, wherein the BOG supplied to the sub engine is BOG that is compressed while passing through all or part of the plurality of compression cylinders included in the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što je BOG poslan u pomoćni motor (200) BOG koji se komprimira prilikom prolaska kroz sve ili dio od više kompresijskih cilindara (14) koje sadrži kompresor (13).
Table 16A: Composition of the Solution Vehiclea. 
21.09.2016. Broj objave europskog patenta:
unless otherwise stated, R1 is absent, C0-10alkyl, cycloC3-10alkyl, bicycloC5-10alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterobicycloC5-10alkyl, spiroalkyl, or heterospiroalkyl, any of which is optionally substituted by one or more independent G11 substituents; 
R'! je Conoalkil, cikloC;,oalkil, bicikloCs.oalkil, aril, heteroaril, aralkil, heteroaralkil, heterociklil, heterobiciklo Csaealkil, spiroalkil ili heterospiroalkil, gdje je bilo koji od njih izborno supstituiran jednim ili više nezavisnih G"' supstituenata;
is H or hydroxy; and Ring A is optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, C1-4 alkyl, C1-4 alkoxy and C3-5 cycloalkyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof. 
Ri je hidroksi; te Prsten A je po izboru supstituiran sa 1 ili 2 supstituenda izabrana iz skupine koju čine halogen, C;.4 alkil, C;.4 alkoksi i Cas cikloalkil; ili na njihove farmaceutski prihvatljive soli, solvate ili hidrate.
a second peptide comprising a sequence consisting of a HLA-A*2402-restricted immunogenic epitope derived from the HLA-A*2402-restricted cryptic epitope recited in (i) by a method according to claim 1, wherein said second peptide is a chimeric polypeptide according to claim 6. 
(ii) drugi peptid koji sadrži slijed koji se sastoji od HLA-A*2402-restrikcijskog imunogeničnog epitopa izvedenog iz HLA-A*2402-restrikcijskog kriptičkog epitopa navedenog u (i) metodom u skladu s patentnim zahtjevom 1, pri čemu je navedeni drugi peptid kimerični peptid u skladu s patentnim zahtjevom 6.
P-toluene sulfonate 0.2% The formulation was prepared by using a suitable stainless steel tank, provided with a stirrer. 
6. trimetilcetilamonijev p-toluen sulfonat 0,2% Formulacija je pripremljena koristeći odgovarajuću zatvorenu posudu od nehrđajućeg čelika s mješalicom.
A pharmaceutical composition comprising the dihydrochloride salt according to claim 1, or a solvate, hydrate or tautomer thereof, and one or more pharmaceutically acceptable excipients. 
Farmaceutska kombinacija naznačena time da sadrži dihidrokloridnu sol prema zahtjevu 1 ili 2, te jedno ili više dodatnih farmaceutskih sredstava.
The compound for use according to claim 1 or claim 2, wherein the compound is administered to the subject in a pharmaceutical composition which comprises a pharmaceutical formulation of: 
Spoj za upotrebu ili upotreba prema zahtjevu 11, pri čemu je oblik monokristala naznačen time da ima uzorak difrakcije X-zraka na prahu prema slici 1.
A safety glove according to claim 8, wherein at least two protective elements are located at the top dorsal part of at least two glove fingers, such that the glove has a protective element on each of the two fingers and said elements have their top part in the shape of an elongated semicircle connected to a half-ring. 
Zaštitna rukavica (2) u skladu s patentnim zahtjevom 6, naznačena time što se najmanje dva zaštitna elementa (1) u skladu s patentnim zahtjevom 1 nalaze na gornjem dorzalnom dijelu najmanje dva prsta rukavice, tako da rukavica ima zaštitni element na svakom od dva prsta.
The method according to claim 6, wherein said oligonucleotide is administered intraperitoneally, intramuscularly, intravenously, intranasally, subcutaneously, intradermally or intrathecally. 
Farmaceutski sastav prema patentnom zahtjevu 3, gdje se farmaceutski sastav primjenjuje intraperitonealno, intramuskularno, intravenozno, intranazalno, potkožno, intradermalno ili intratekalno.
is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or, substituted or unsubstituted heterocyclic; 
je supstituirani ili nesupstituirani aril ili supstituirani ili nesupstituirani heteroaril;
The medicament delivery device of claim 1, wherein the first mechanically coded interface device is arranged to match and interact with the third mechanically coded interface device arranged on the distal housing part, and the second mechanically coded interface device is arranged to match and interact with the fourth mechanically coded interface device arranged on the proximal housing part. The medicament delivery device of claim 1, wherein the interface member is fixedly connected to a distal end of the medicament container such that an attempted removal of the interface member will deform the interface member. 
Uređaj za isporuku lijeka prema zahtjevu 1, naznačen time da su navedena prva mehanički kodirana sredstva sučelja (51; 151) postavljena tako da su usklađena i u interakciji su s trećim mehanički kodiranim sredstvima sučelja (11; 111) smještenim na distalnom dijelu kućište, te pri čemu su navedena druga mehanički kodirana sredstva sučelja (52; 152) postavljena tako da su usklađena i u interakciji su sa četvrtim mehanički kodiranim sredstvima sučelja (22; 122) smještenim na proksimalnom dijelu kućišta.
The method of claim 1, wherein the fusion protein is administered at a dose of 15 mg/kg of the subject's body weight. 
modificirani angiopoietin se primjenjuje u dozi od 15 mg/kg tjelesne težine subjekta; i/ili
• when the medication receptacle (2) is engaged with the distal end of the housing (3) the reset element (11) is in the operational state and 
* kada je spremnik lijeka (2) spojen sa stražnjim krajem kućišta (3), element za resetiranje (11) je u radnom položaju, a
In particular aspects of the invention the biological targets comprise nucleic acids and the encoded probes are oligonucleotides, and in some aspects, there are two encoded probes for each of the multiple nucleic acid targets. 
Metoda prema patentnom zahtjevu 3, gdje su biološke mete nukleinske kiseline i kodirane probe su oligonukleotidne probe. Metoda prema patentnom zahtjevu 1 ili 4, gdje postoje dve oligonukleotidne probe za svaku od nukleinsko kiselinskih bioloških meta.
Use of the antibodies according to claim 1 and 2 or in form of a pharmaceutical composition according to claim 10 comprising PRLR antibodies or antigen-binding fragment according to claim 1 and 2 for parenteral administration, whereby methods of parenteral delivery include topical, intra-arterial, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration. 
Farmaceutski pripravak prema zahtjevu 14 koji sadrži PRLR antitijela ili fragment koji veže antigene ili njihove sazrele varijante prema bilo kojem od zahtjeva 1 do 4, naznačen time da je za uporabu putem parenteralno davanje, pri čemu postupci parenteralne primjene uključuju lokalnu, intraarterijsku, intramuskularnu, potkožnu, intramedulamu, intratekalnu, intraventrikularnu, intravenoznu, intraperitonealnu, intrauterinu, vaginalnu, ili intranazalnu primjenu.
The fermentation process of any one of the preceding claims wherein the antifoaming agent is Polydimethylsiloxane. 
Fermentacijski postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je sredstvo protiv pjenjenja polidimetilsiloksan.
A compound for use as claimed in claim 1, wherein said disease is selected from chronic pain, neuropathic pain, postoperative pain, cancer pain, osteoarthritic pain, rheumatoid arthritic pain, neuralgia, fibromyalgia, neuropathies, fibromyalgia, algesia, nerve injury, migraine, headache, itch, painful bladder syndrome, interstitial cystitis, detrusor overactivity, urinary incontinence, neurogenic detrusor overactivity, idiopathic detrusor overactivity, benign prostatic hyperplasia, anxiety, depression and cold-induced pulmonary hypertension, COPD and asthma. 
Spoj za upotrebu prema patentnom zahtjevu 1, naznačen time što je navedena bolest izabrana od kronične boli, neuropatske boli, postoperativne boli, boli od karcinoma, osteoartritičke boli, boli od reumatoidnog artritisa, neuralgije, fibromialgije, neuropatija, fibromialgije, algezije, povrede živaca, migrene, glavobolje, svraba, sindroma bolnog mjehura, intersticijalnog cistitisa, prekomjerne aktivnosti detruzora, urinarne inkotinencije, neurogene prekomjerne aktivnosti detruzora, idiopatske prekomjerne aktivnosti detruzora, benigne hiperplazije prostate, anskioznosti, depresije 1 plućne hipertenzije inducirane prehladom, COPD i astme.
Conventional non-photo polymerisable dental materials are based on a two component resin system. 
Pogodni ne-foto dentalni materijali koji polimeriziraju su zasnovani na dvodijelnom sustavu smola.
Netupitant for use according to claims 1-5, wherein: 
Netupitant za uporabu u skladu s patentnim zahtjevima 1-4, pri čemu:
The composition as claimed in claim 1, wherein the surfactant is a surfactant protein and a weight fraction of all surfactant proteins, based on the total weight of the composition, is greater than 1.0 mg/l. 
Kompozicija za primjenu u postupku sukladno zahtjevu 3, naznačena time, što je težinski udio surfaktanta proteina, bazirano na ukupnoj težini kompozicije, veći od 1,0 mg/l. HR P20191387 T1
A compound of formula (IV) as claimed in claim 1 or claim 6, wherein D is C(O), and Ar1 and Ar2 are substituted or unsubstituted oxazole, thiazole and ozadiazole. 
Spojevi formule (IV) prema zahtjevu 1 ili 6, naznačeni time, da D je C(O), a Ar1 i Ar2 su supstituiran ili nesupstituiran fenil ili het, gdje je spomenuti het supstituiran ili nesupstituiran oksazol, tiazol ili oksadiazol.
The method according to claim 1, wherein the L1 signaling information has data slice ID information that identifies the data slice. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu informacija signaliziranja L1 ima ID informaciju podatkovnog reza koja identificira podatkovni rez.
This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl, heptyl, octyl, nonyl and the like. 
Pojam je opisan primjerom skupinama poput metilne, etilne, n-propilne, izopropilne, n-butilne, izobutilne, fert-butilne, n-heksilne, heptilne, oktilne, nonilne i sličnih.
ON represents an oligonucleotide comprising at least 4 nucleotide or nucleotide analogue building blocks, comprising the steps: 
ON predstavlja oligonukleotid koji obuhvaća najmanje 4 nukleotida ili građevne blokove nukleotidnih analoga, a koji obuhvaća korake:
Lyophilization process was performed as before for Formulations ET-NF A, ET-NF B and ET-NF F (Table 1X). 
Proces liofilizacije je izveden kao u prethodnom slučaju za oblike ET-NF A, ET-NF B i ET-NF F (Tablica IX).
The method as in claim 11, the method employing an apparatus to prepare the predispersion and feed the predispersion into the first container, wherein the apparatus is effective for mixing a material and wherein the apparatus comprises the device and a mixing portion comprising a second container; wherein the second container has a downstream outlet defining an opening and is sealably connected to the device around and proximal to the upstream apertures of the device in such a way that the device restricts the opening of the downstream outlet of the second container to the openings of the upstream apertures of the device; and the apparatus functions in such a way that when the second container of the apparatus contains a material, the material can be discharged from the apparatus via the device without clogging the device. 
Postupak kao u zahtjevu 11, naznačen time, da koristi aparat za pre-disperziju i punjenje pre-disperzije u prvi spremnik, pri čemu je aparat učinkovit za miješanje materijala 1 pri čemu aparat podrazumijeva uređaj 1 dio za miješanje koji sadrži drugi spremnik; pri čemu drugi spremnik ima ispust nizvodno koji definira otvor i nepropusno je spojen oko i u blizini otvora uzvodno na uređaju na način da uređaj ograničava otvaranje ispusta nizvodno drugog spremnika prema otvorima uzvodno na uređaju; i aparat djeluje na takav način da se, kada drugi spremnik aparata sadrži materijal, materijal može biti ispušten 1z aparata putem uređaja bez začepljenja uređaja.
A solution for use according to claim 8, wherein the concentration of the colistimethate sodium ranges from 90 to 110 mg A/mL. 
Otopina za uporabu sukladno patentnom zahtjevu 8, pri čemu je koncentracija kolistimetat natrija u rasponu od 90 do 110 mg A/mL.
The compound or a pharmacologically acceptable salt thereof according to claim 5, wherein R1 is a group represented by the following general formula (3): wherein R3, R4 and R5 are as defined for R3, R4 and R5 in claim 5. 
Spoj, ili njegova farmakološki prihvatljiva sol, u skladu s patentnim zahtjevom 5, naznačen time što je R1 skupina prikazana sljedećom općom formulom (3): [image], gdje su R3, R4 i R5 definirani kao za R3, R4 i R5 u patentnom zahtjevu 5.
for each epitope selected in step (iv), testing if the CTLs generated against the optimized epitope also recognize its cognate native epitope, and selecting those for which the test is positive. 
(vi) za svaki epitop odabran u koraku (v), ispitivanje prepoznaju li CTL-ovi stvoreni protiv optimiranog epitopa također 1 svoj poznati nativni epitop 1 odabir onih za koji je test pozitivan.
The method of claim 1, wherein the metal carbonyl compound is supported on a solid, optionally wherein (i) the solid support is selected from the group consisting of inorganic solids and polymer supports, or wherein (ii) the solid support is selected from the group consisting of: silica, glass, alumina, zirconia, diatomaceous earth, metal oxides, metal salts, ceramics, clays, molecular sieves, kieselgur, and titanium dioxide, or wherein (iii) the solid support is selected from the group consisting of silica gel, alumina, and glass. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je metalni karbonilni spoj na čvrstom nosaču, izborno gdje (i) čvrsti nosač se bira iz skupine koju čine anorganske krutine i polimerni nosači, ili gdje (ii) čvrsti nosač se bira iz skupine koju čine: silicijev dioksid, staklo, aluminijev oksid, cirkonijev dioksid, diatomejska zemlja, metalni oksidi, metalne soli, keramika, gline, molekulska sita, kizelgur, te titanijev dioksid, ili gdje (ili) čvrsti nosač se bira iz skupine koju čine silicijev dioksid gel, aluminijev oksid, te staklo.
The anamorelin monohydrochloride or composition comprising anamorelin monohydrochloride of the present invention can be present in an isolated state or, alternatively, it can be formulated into a pharmaceutical dosage form (i.e., pharmaceutical composition) that comprises a therapeutically effective amount of the compound and one or more pharmaceutically acceptable excipients. 
4. - Farmaceutski sastav koji sadrži: a) terapeutski efikasnu količinu anamorelin monohidroklorida prema patentnim zahtjevima 1, 2 ili 3; 1 b) jedan ili više farmaceutski prihvatljivih ekscipijenata.
dehydrating the compound of formula (22), or salt thereof, to obtain the compound according to formula (21), or salt thereof, 
(22) c) dehidratacija spoja formule (22) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (21) ili njegova sol:
The isolated nucleic acid molecule of claim 7, wherein the secretory signal sequence is a Listeria monocytogenes ActA signal sequence, or an in frame ActA-N100 sequence selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31, or an amino acid sequence having at least 90% sequence identity to said ActA-N100 sequence. 
Izolirana molekula nukleinske kiseline prema zahtjevu 7, naznačena time, Ga sekrecijski signalni slijed je Listeria monocytogenes ActA signalni slijed, ili je u okviru ActA-N 100 slijeda odabranog 12 skupine koja se sastoji iz SEG ID NO: 28, SEQ ID NO: 29, SEG ID NO: 301 SEQ ID NO: 31, ili aminokiselinskog slijeda koji je u najmanje 90% slijeda identičan s navedenim ActA-N100 slijedom.
forming a biphasic composition comprising (i) a first organic phase, and (ii) an alcoholic-caustic phase containing trans-(−)-A9-tetrahydrocannabinol; 
(a) formiranje bifaznog sastava koji sadrži (i) prvu organsku fazu, i (ii) alkoholno-kaustičnu fazu koja sadrži trans- (-)-A"-tetrahidrokanabinol;